The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Idebenone Treatment In Leber's Hereditary Optic Neuropathy
Abstract
Sir, We have read with great interest the results presented by Klopstock et al. (2011) concerning the RHODOS study on a clinical trial with idebenone in Leber's hereditary optic neuropathy (LHON) and we would like to share our own experience of idebenone therapy in LHON. Idebenone has been an approved drug (Mnesis®, Takeda Italia Farmaceutici) in Italy since the early 1990s and, after the initial report by Mashima et al. (1992) on its possible efficacy in LHON, we offered this therapeutic option to all of our new consecutive patients with LHON, almost all of whom accepted treatment. Idebenone was given after informed consent following the regulation for ‘off-label’ drug administration and was provided for free by the National Health Service, under the legislation for certified rare disorders. Patients were initially treated with 270 mg/day (Cortelli et al., 1997; Carelli et al., 1998a, b), but following the reports on idebenone treatment in Friedreich ataxia, the dosages were increased to 540–675 mg/day (Rustin et al., 1999; Kearney et al., 2009). To evaluate retrospectively the efficacy of idebenone therapy, we reviewed all of our patients with LHON, idebenone treated and untreated, after approval of the institutional Internal Review Board. Inclusion criteria for treated patients were the initiation of therapy within 1 year after visual loss in the second eye, and for all patients (treated and untreated) age at onset of at least 10 years and a follow-up of at least 5 years. We included only patients treated within 1 year after onset because this is the time frame to reach the nadir of the visual loss and the probability of spontaneous recovery of vision is highest in the following 5 years (Nikoskelainen et al., 1983; Barboni et al., 2005, 2010; Spruijt et al., 2006). We also excluded subjects with disease onset before 10 years of age (childhood cases), because of their well-established benign prognosis (Carelli et al., 2004; Barboni et al., 2006; Yu-Wai-Man et al., 2011). The untreated patients were considered as a control cohort. These patients lost their vision and were followed before idebenone treatment became an option, thus none of them was offered and declined the use of idebenone. For the sake of uniformity in assessment of visual function in all patients, we chose visual acuity of the best and the worst eye at the last available examination as our primary outcome measure. Recovery of visual acuity was considered for patients or eyes (some patients recovered vision in only one eye) with a gain of at least two lines on Snellen acuity or a change from ‘off chart’ to ‘on chart’, as previously established (Nikoskelainen et al., 1996; Barboni et al., 2005). Given the retrospective nature of this study, all visual acuity evaluations were not blinded to treatment status. For all patients, we also determined (i) age of disease onset; (ii) time lapse between loss of visual acuity in the eyes; (iii) time between disease onset and start of therapy; (iv) time between disease onset and recovery of visual acuity; (v) average therapy dosage; and (vi) therapy duration. The interval between loss of vision in the eyes was evaluated only for the patients with asynchronous onset of symptoms, which was 56% for 11778/ND4, 50% for 3460/ND1 and 67% for 14484/ND6 mutation, having excluded three outliers (time lapse of 23, 180 and 504 months, respectively), which exceeded 2 SD from the mean. The difference in sex distribution between the group of idebenone-treated patients and the group of untreated patients was evaluated using χ2 test. Student t-test was performed for comparison of the age at onset and visual acuity of the best and worst eye evaluated at the nadir of visual loss (between 6 months and 1 year after disease onset) between the two groups. To evaluate the impact of all covariates on visual recovery, we used a Cox proportional hazards model. A first model included gender, age at onset, type of mutation and therapy/no therapy as independent variables and visual recovery as outcome. In a second model, we added the time between disease onset and start of therapy, the average therapy dosage and the therapy duration as variables. In both models, a backward stepwise method was applied to obtain the best model in which all included variables had a significant P-value. Furthermore, we separately compared the interval between asynchronous disease onset in the first and the second eye in patients treated before the involvement of the second eye (‘in-between-eyes’), patients treated after the involvement of the second eye and patients not treated by using the Kruskall–Wallis test followed by a post hoc Mann–Whitney U test. For all analyses, two-sided P < 0.05 was considered statistically significant. Overall, 103 patients with LHON, carrying a primary mitochondrial DNA mutation were included in this study. Forty-four patients (37 males) were either treated within 1 year after the onset of visual acuity loss in the second e
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Cited by
Disturbed mitochondrial dynamics and neurodegenerative disorders
Burté, F., Carelli, V., Chinnery, P. F., & Yu-Wai-Man, P. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.228 · Cited by 660
Self-citationMetabolic control of cell death
Green, D. R., Galluzzi, L., & Kroemer, G. (2014) · Science · doi:10.1126/science.1250256 · Cited by 647
The clinical maze of mitochondrial neurology
DiMauro, S., Schon, E. A., Carelli, V., & Hirano, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.126 · Cited by 353
Self-citationYu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232
Self-citationCarelli, V., Carbonelli, M., de Coo, I. F., Kawasaki, A., Klopstock, T., Lagrèze, W. A., La Morgia, C., Newman, N. J., Orssaud, C., Pott, J. W. R., et al. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000570 · Cited by 228
Self-citation
Metadata
- Authors
- Carelli, V., La Morgia, C., Valentino, M. L., Rizzo, G., Carbonelli, M., De Negri, A. M., Sadun, F., Carta, A., Guerriero, S., Simonelli, F., Sadun, A. A., Aggarwal, D., Liguori, R., Avoni, P., Baruzzi, A., Zeviani, M., Montagna, P., & Barboni, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-08-02
- Volume
- 134
- Issue
- 9
- Pages
- e188-e188
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1602227394
- Cited by
- 241
- References
- 2
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Idebenone Treatment In Leber's Hereditary Optic Neuropathy. https://app.cochat.ai/papers/10.1093/brain/awr180
- The paper
- Carelli, V., La Morgia, C., Valentino, M. L., Rizzo, G., Carbonelli, M., De Negri, A. M., Sadun, F., Carta, A., Guerriero, S., Simonelli, F., Sadun, A. A., Aggarwal, D., Liguori, R., Avoni, P., Baruzzi, A., Zeviani, M., Montagna, P., & Barboni, P. (2011). Idebenone Treatment In Leber's Hereditary Optic Neuropathy. Brain. https://doi.org/10.1093/brain/awr180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.